Clinical Trial: Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246187) titled 'Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department' on Nov. 14.

Brief Summary: The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.

Study Start Date: Nov. 06

Study Type: INTERVENTIONAL

Condition: Cannabinoid Hyperemesis Syndrome

Intervention: DRUG: Olanzapine 10 milligram

olanzapine 10 mg IM

DRUG: Haloperidol

Haloperidol 5 mg IM

Recruitment Status: RECRUITING

Sponsor: Mercy B...